This edition of Pharmalot’s regular “comings and goings” column, published Sept. 18, 2026, highlights personnel activity in the biotech and pharmaceutical community. The column functions as a roundup of recent hires, promotions, and filled positions and encourages organizations and individuals to submit their own announcements for possible inclusion.
The publicly available portion of the item is concise and selects a single individual to spotlight this week. Additional material related to the column is marked as exclusive to STAT+ subscribers; therefore, details beyond the excerpt are not available in the source provided.
The article reports that IN8bio has hired Oxana Polyakova as senior vice president, research & development. Pharmalot presents Polyakova’s appointment as the featured personnel change for this week’s installment of the column.
The announcement in the excerpt is brief: it states the new title and employer and identifies Polyakova as the person being highlighted, without providing additional commentary on responsibilities, timing, or strategic objectives tied to the appointment in the publicly visible text.
Within the excerpt, the article notes Polyakova’s most recent prior position: she served as chief scientific officer at LAVA Therapeutics. No further information about her tenure, accomplishments, or the specifics of her role at LAVA Therapeutics appears in the accessible portion of the article.
Because the piece available to non-subscribers contains only this level of detail, the source does not report additional professional background, education, or statements from Polyakova or IN8bio in this excerpt. Those details may be part of the subscriber-only content.
Pharmalot uses this recurring feature to disseminate industry hiring news. The column explicitly invites submissions: if you hired someone new, promoted an internal candidate, or filled a long-open position, Pharmalot asks readers to send the information so it can be shared with its audience. The invitation is framed as inclusive and encouraging: the column states it will find a home for submitted changes and urges readers not to be shy about sharing updates.
The publicly visible excerpt includes this call for submissions but does not specify submission formats, contact addresses for press releases beyond the general author contact information, nor editorial criteria for selection. Those operational details are not reported in the accessible portion of the article.
The article segment on the public site includes a clear STAT+ notice indicating that the remainder of the story is available only to subscribers. The excerpt contains subscription prompts, pricing options, and a message that the rest of the article requires STAT+ access. As a result, the publicly available content provides a limited snapshot: the primary verifiable facts in the excerpt are the appointment at IN8bio and Polyakova’s previous role at LAVA Therapeutics.
Any additional reporting, context, or expanded list of other comings and goings that may be contained in the full STAT+ article is not accessible in the source excerpt and therefore is not reported here.
The column is authored by Ed Silverman, identified as Pharmalot columnist and senior writer. The article carries a Sept. 18, 2026 date. An email address for Ed Silverman is shown in the source excerpt for contact. The publicly visible portion also notes the column’s regular newsletters (Pharmalittle and Pharmalot) and includes links to subscription and account pages.
Notes and limitations
If you have a confirmed hire, promotion, or other personnel change you would like Pharmalot to consider, the article encourages submitting that information, and Ed Silverman’s contact details appear in the published excerpt for potential follow-up.